Phenotypic screening is once again popular at many large pharmaceutical companies, as the targeted drug discovery approach is being considered too limiting in certain ways, says Joanne Kotz at SciBX. "Phenotypic screens used to be the mainstay of drug development," Kotz says. Since the 1980s, advances in molecular biology and genomics have led drug companies to use targeted screening method to develop drugs.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.

The New York Times reports on the shifting interpretations of what some genetic variants mean over time.

In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.

MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.